Brief: Pelthos Therapeutics Announces Fourth Quarter And Full Year 2025 Financial Results
19/03/2026 12:02
March 19 (Reuters) - Pelthos Therapeutics Inc PTHS.A: PELTHOS THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS PELTHOS THERAPEUTICS INC QTRLY TOTAL REVENUE 9.4 MILLION PELTHOS THERAPEUTICS INC QTRLY NET LOSS PER COMMON SHARE $6.87 PELTHOS THERAPEUTICS INC: HAVE COMMERCIAL INFRASTRUCTURE AND EXPERIENCE TO CONTINUE TO GROW ZELSUVMI AND LAUNCH AND GROW XEPI AND XEGLYZE PELTHOS THERAPEUTICS INC QTRLY TOTAL REVENUE $9.4 MILLION (ADDS DROPPED CURRENCY) Source text: ID:nGNX4HxT42 Further company coverage: PTHS.A ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Pelthos Therapeutics
See all newsPelthos Therapeutics falls as co says will restate Q1 financial statements
Brief: Pelthos Therapeutics Financial Statements Should No Longer Be Relied Upon For Quarter Ended March 31- SEC Filing
Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoption
Brief: Pelthos Therapeutics Announces CFO Transition
Brief: Pelthos Therapeutics Announces First Patient Dosed In Phase 1B/2A Clinical Trial Of Ct2000 In Eye Pain